Daphne Karydas serves as Executive at Mineralys Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Daphne Karydas has executed 5 insider transactions totaling $689.8K, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 19, 2026 involved receiving (via award) 8,300 shares valued at $0.
Daphne Karydas currently holds 8,300 shares of Mineralys Therapeutics, Inc. (MLYS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Daphne Karydas has been a net seller of MLYS stock. They have purchased $0 and sold $689.8K worth of shares.
Daphne Karydas's most recent insider trade was on Feb 19, 2026, when they sold 8,300 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Nov 13, 2025 | MLYS | $153.0K | Option Exercise | 15,000 | $10.20 | Discretionary |
| Nov 13, 2025 | MLYS | $463.4K | Sale | 10,115 | $45.81 | Discretionary |
| Nov 13, 2025 | MLYS | $226.5K | Sale | 4,885 | $46.36 | Discretionary |